In the REVERT trial, short-term rosiglitazone therapy significantly lowered insulin resistance, high sensitivity C-reactive protein (hsCRP), and von Willebrand factor (vWF) [15], suggesting that PPARγ agonists may reduce endothelial dysfunction in patients with CKD. Here, PPARG is linked to chronic kidney disease.